Inhibitors of KEAP1-Nrf2 protein-protein interaction
申请人:Janssen Pharmaceutica NV
公开号:US10947252B2
公开(公告)日:2021-03-16
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION
申请人:Janssen Pharmaceutica N.V.
公开号:EP3833662A2
公开(公告)日:2021-06-16
[EN] INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION<br/>[FR] INHIBITEURS DE L'INTERACTION PROTÉINE-PROTÉINE KEAP1-NRF2
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2020041169A2
公开(公告)日:2020-02-27
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
申请人:Janssen Pharmaceutica NV
公开号:US20200055874A1
公开(公告)日:2020-02-20
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.